Tema Etfs LLC Makes New $926,000 Investment in Xencor, Inc. $XNCR

Tema Etfs LLC bought a new stake in Xencor, Inc. (NASDAQ:XNCR) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 60,457 shares of the biopharmaceutical company’s stock, valued at approximately $926,000.

A number of other hedge funds have also made changes to their positions in the stock. Primecap Management Co. CA boosted its holdings in shares of Xencor by 1.4% during the third quarter. Primecap Management Co. CA now owns 10,675,022 shares of the biopharmaceutical company’s stock worth $125,218,000 after purchasing an additional 147,700 shares during the period. Legal & General Group Plc increased its stake in Xencor by 603.7% in the 3rd quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock valued at $14,932,000 after buying an additional 1,092,095 shares during the period. UBS Group AG increased its stake in Xencor by 51.4% in the 3rd quarter. UBS Group AG now owns 1,175,267 shares of the biopharmaceutical company’s stock valued at $13,786,000 after buying an additional 399,071 shares during the period. Baker BROS. Advisors LP lifted its position in Xencor by 64.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,102,106 shares of the biopharmaceutical company’s stock worth $12,928,000 after buying an additional 431,675 shares in the last quarter. Finally, Nantahala Capital Management LLC boosted its stake in shares of Xencor by 34.1% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,100,000 shares of the biopharmaceutical company’s stock valued at $12,903,000 after buying an additional 279,897 shares during the period.

Insider Transactions at Xencor

In other news, SVP Celia Eckert sold 3,244 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $11.25, for a total transaction of $36,495.00. Following the completion of the transaction, the senior vice president directly owned 78,685 shares in the company, valued at $885,206.25. This represents a 3.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP John R. Desjarlais sold 4,118 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $11.25, for a total value of $46,327.50. Following the transaction, the vice president directly owned 266,333 shares of the company’s stock, valued at $2,996,246.25. This trade represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 44,020 shares of company stock valued at $499,817 over the last three months. Company insiders own 4.76% of the company’s stock.

Analyst Ratings Changes

XNCR has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research report on Friday, March 27th. Wall Street Zen downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Barclays upped their price target on Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $13.00 price objective (down from $18.00) on shares of Xencor in a report on Tuesday, March 24th. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $24.38.

Xencor Stock Up 2.2%

Shares of NASDAQ:XNCR opened at $12.81 on Friday. Xencor, Inc. has a 52 week low of $6.92 and a 52 week high of $18.69. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.25 and a current ratio of 6.25. The company has a market capitalization of $939.49 million, a PE ratio of -10.33 and a beta of 0.99. The company has a 50 day moving average price of $12.01 and a two-hundred day moving average price of $13.43.

Xencor (NASDAQ:XNCR) last posted its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.55. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The firm had revenue of $28.24 million for the quarter, compared to analyst estimates of $29.97 million. During the same period in the previous year, the company posted ($0.62) earnings per share. The company’s revenue for the quarter was down 46.6% on a year-over-year basis. Analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.